Niagen Bioscience
NAGE
82 hedge funds and large institutions have $49.9M invested in Niagen Bioscience in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 13 closing their positions.
87% more call options, than puts
Call options by funds: $478K | Put options by funds: $255K
0.09% more ownership
Funds ownership: 29.64% → 29.72% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 83 → 82 (-1)
34% less capital invested
Capital invested by funds: $75.8M → $49.9M (-$25.9M)
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$2.77M |
| 2 |
Renaissance Technologies
New York
|
+$1.04M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$657K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$496K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.72M |
| 2 |
Barclays
London,
United Kingdom
|
-$1.55M |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$1M |
| 4 |
Millennium Management
New York
|
-$845K |
| 5 |
Goldman Sachs
New York
|
-$207K |
NAGE Hedge Fund Activity: Q1 2022 in Review
82 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2022, worth a combined $49.9M — down 34% from $75.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NAGE and 12 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 18 added.
The largest buyer was Tieton Capital Management, adding an estimated $2.77M. The largest seller was Bank of America, cutting an estimated $1.72M.
- 82 institutional investors held Niagen Bioscience (NAGE) as of Q1 2022, down from 83 in Q4 2021.
- Funds reported $49.9M of Niagen Bioscience stock for Q1 2022, down 34% quarter-over-quarter.
- 12 funds opened new Niagen Bioscience positions in Q1 2022 and 13 closed out, a net change of -1 holder.
- The largest Niagen Bioscience buyer in Q1 2022 was Tieton Capital Management, an estimated $2.77M added.
- The largest Niagen Bioscience seller in Q1 2022 was Bank of America, an estimated $1.72M sold.
Based on aggregated 13F filings for Q1 2022.